Page last updated: 2024-11-13

oxt-328

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OXT-328: a synthetic antineoplastic phospho-sulindac; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25181435
SCHEMBL ID11916853
SCHEMBL ID17165301
MeSH IDM0551024

Synonyms (6)

Synonym
oxt-328
SCHEMBL11916853
SCHEMBL17165301
1118973-90-2
cid 25181435
4-diethoxyphosphoryloxybutyl 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Topical application of PSH is efficacious and safe in the treatment of Freund's adjuvant-induced arthritis; has a favorable pharmacokinetic profile; and likely acts by suppressing key pro-inflammatory signaling pathways."( Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Cheng, KW; Huang, L; Mackenzie, GG; Mattheolabakis, G; Ouyang, N; Rigas, B, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
" Study results show that P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac."( Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Huang, L; Komninou, D; Kopelovich, L; Mackenzie, GG; Ouyang, N; Rigas, B; Sun, Y; Vrankova, K; Xie, G, 2011
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (92.86)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.08 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.85 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]